Fundz

TRex Bio, Inc. raised $84 million in a Series B round led by Delos Capital to advance its immunology programs into clinical development.

PUBLIC · TRXBNov 13, 2024

Amount Raised

$84 Million

Round Type

Series B

South San FranciscoBiotechnologyHealth CareTherapeutics

Investors

Avego Bioscience CapitalPolaris PartnersAlexandria Venture InvestmentsJohnson & JohnsonPfizer VenturesSV Health InvestorsEli Lilly And CompanyAgent CapitalDelos Capital

Description

TRex Bio, Inc. announced the close of an $84 million Series B financing round intended to advance its lead candidate TRB-061 through early clinical trials. The financing was led by Delos Capital with participation from several existing and new investors.

Quick answer

TRex Bio raised $84 Million in a Series B round, dated November 13, 2024. Investors: Avego Bioscience Capital, Polaris Partners, Alexandria Venture Investments, Johnson & Johnson, Pfizer Ventures, SV Health Investors, Eli Lilly And Company and Agent Capital. TRex Bio is based in South San Francisco, California, United States.

How much did TRex Bio raise?
TRex Bio raised $84 Million in a Series B round on November 13, 2024.
Who invested in TRex Bio?
Avego Bioscience Capital, Polaris Partners, Alexandria Venture Investments, Johnson & Johnson, Pfizer Ventures, SV Health Investors, Eli Lilly And Company and Agent Capital are named as investors in this round.
What does TRex Bio do?
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and..
Where is TRex Bio based and how big is it?
TRex Bio is based in South San Francisco, California, United States. Fundz records about 62 employees.
Who are the decision-makers at TRex Bio?
Fundz holds 1 contact at TRex Bio. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at TRex Bio, and when

A new round usually means TRex Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TRex Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TRex Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TRex Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TRex Bio

Location

South San Francisco, California, United States

About

TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TRex Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for TRex Bio's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

TRex Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.